CClinicalTrials.gg
CompletedNCT01882036Updated Feb 14, 2023

Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus

An interventional study of Gastric Bypass w/ matched hypocaloric diet and Hypocaloric diet in Type 2 Diabetes Mellitus and Insulin Resistance, sponsored by University of Minnesota. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by University of Minnesota · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2011, registered Jun 2012).
Phase
Not applicable
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The focus of this proposal is to define the mechanism by which bariatric surgery acutely improves insulin sensitivity. Our central hypothesis is that drastically reduced caloric intake early after Bariatric surgery improves the pro-inflammatory profile of macrophages, which in turn improves insulin sensitivity and glucose homeostasis.

Read the detailed description

Bariatric surgery quickly improves tissue specific insulin sensitivity. Changes in glucose metabolism are seen within days after surgery, prior to any significant weight loss--raising the question of a difference between dietary restriction and early food intake after surgery. A major factor in the development of insulin resistance is obesity. It has been noted that by 3 months following Roux-en Y gastric bypass surgery in obese patients with (T2DM), fasting glucose and insulin levels are improved independent of weight loss, insulin resistance in muscle is lowered, and that the pro-inflammatory profile of resident microphages is lowered improving insulin sensitivity.

The focus of this proposal is to define the mechanism by which bariatric surgery improves impacts insulin sensitivity. Our long-term goal is to correlate these changes with direct measures of adipose tissue insulin resistance to develop novel immunotherapies towards reducing insulin resistance without surgery.

Our central hypothesis is that gastrointestinal rearrangement by various mechanisms impacts adipose tissue and improves the pro-inflammatory profile of macrophages improving insulin sensitivity and glucose homeostasis. To test this hypothesis we propose the following aims:

Specific Aim 1. Recruit a patient population and measure insulin sensitivity using homeostatic model assessment (HOMA) to measure insulin resistance (IR), cytokines, incretins, and serum adipokines in morbidly obese patients • prior to and 7-10 days following bariatric surgery while on a hypocaloric diet (surgery group) and •prior to and 7-10 days while following hypocaloric diet similar to bariatric surgery (diet group). Subjects will be assigned to the two arms; subjects assigned to the hypocaloric diet may be offered bariatric surgery after completion of the diet.

Specific Aim 2.

  • Profile inflammatory macrophages, T cells and secreted factors in subcutaneous and visceral adipose tissue of patients prior to and following RYGB and hypocaloric diet treatments. • prior to and 7-10 days following surgery
  • prior to and 7-10 days following hypocaloric diet similar to bariatric surgery

Specific Aim 3.

Assess the effects of bariatric surgery on ROS (reactive oxygen species) production, expression of transcription factors and enzymes of mitochondrial biogenesis, tissue FABP4, and biomarkers of oxidative stress and protein carbonylation in patients prior to and following surgery and in control diet subjects maintained on hypocaloric diet.

Specific Aim 4.

Determine the impact of bariatric surgery on lipolysis and the role of TLQP-21 (a genetically derived peptide that increases energy expenditure and prevents the early phase of diet-induced obesity).

02

Conditions studied

  • Type 2 Diabetes Mellitus
  • Insulin Resistance
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 57 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.

Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria::

  1. Candidate for RYGB gastric bypass with insurance approval.
  2. Willing to accept randomization to either immediate surgery, or delayed surgery after diet study.
  3. Willing to undergo two sessions of testing before, and ten days after surgery (or initiation of dietary intervention).
  4. BMI 35-45kg/m2
  5. Pre-diabetes (ADA criteria) or T2DM with HbA1c\< 8%.

Exclusion criteria:

  1. T1DM.
  2. Serious illness such as cancer, active chronic infection, cardiovascular disease greater that New York Heart Association class 2, chronic renal failure, chronic lung disease.
  3. Inflammatory or celiac intestinal disease.
  4. Untreated thyroid disease.
  5. Serious psychiatric disease.
  6. Excessive alcohol use.
  7. Illicit drug use. -
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Active comparator
    Gastric Bypass w/ matched hypocaloric diet

    Procedure: Gastric Bypass w/ matched hypocaloric diet

  • Active comparator
    Hypocaloric Diet

    Other: Hypocaloric diet

Interventions

  • ProcedureGastric Bypass w/ matched hypocaloric diet

    Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days

  • OtherHypocaloric diet

    Hypocaloric liquid diet for 10 days

06

What researchers measure

Primary outcomes

  1. Measure homeostasis model assessment i.e. estimated change in insulin resistance (HOMA-IR) index

    Time frame: Seven days before and 10 days following RYGB or hypocaloric diet similar to RYGB patients

07

Study locations

1 site
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01882036
Lead sponsor
University of Minnesota
Collaborators
American Diabetes Association
Responsible party
Sponsor
First posted
Jun 20, 2013
Start date
Nov 2011
Primary completion
Jul 10, 2018
Completion
Jul 10, 2018
Last update
Feb 14, 2023

Study contacts

Sayeed Ikramuddin, MD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion